10% Stockholder Files Intent to Sell Over $500K in Shares Amidst Delisting Threat
TNYA sits 95% above its 52-week low of $0.36 on elevated volume (2.0× avg).
Summary
A significant 10% stockholder, COLUMN GROUP III-A, LP, has filed a Form 144 indicating intent to sell an additional $504,788 worth of Tenaya Therapeutics common stock, following recent sales and a Nasdaq delisting notice.
Key Events · Ownership and Investor Activity · TNYA
-
Major Shareholder Intent to Sell
COLUMN GROUP III-A, LP, a 10% stockholder, intends to sell 742,663 shares of common stock, valued at approximately $504,788.
-
Recent Selling Activity
This follows the sale of 182,295 shares by the same filer on February 10, 2026, generating gross proceeds of $148,770.95.
-
Context of Delisting Notice
The selling activity occurs shortly after Tenaya Therapeutics received a Nasdaq delisting notice on January 30, 2026, for failing to meet the minimum bid price requirement.
Analysis · TNYA · Life Sciences
This Form 144 filing signals a continued reduction in stake by a major institutional investor, COLUMN GROUP III-A, LP. The proposed sale of over $500,000 in shares, combined with previous sales reported in the last three months, indicates a sustained divestment. This activity is particularly notable given the company's recent receipt of a Nasdaq delisting notice on January 30, 2026, which raises concerns about the company's financial stability and future prospects. The repeated selling by a significant shareholder during a period of corporate distress could further pressure the stock.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TNYA was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $147.2M. The 52-week trading range was $0.36 to $2.35. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.